Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_2

60%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

3(60.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(2)

Detailed Status

Completed3

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (60.0%)

Phase 32 (40.0%)

Trials by Status

terminated240%

completed360%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_3

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

NCT07197034

terminatedphase_3

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

NCT06828861

completedphase_2

Clinical Trials (5)

Showing 5 of 5 trials

NCT07197034Phase 3

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

Terminated

NCT06828861Phase 3

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

Terminated

NCT05153434Phase 2

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Completed

NCT05215847Phase 2

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

Completed

NCT05121441Phase 2

Study to Evaluate ARD-101 in Adults With Obesity

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5